These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
287 related items for PubMed ID: 22546763
1. In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia. Dhabaan GN, AbuBakar S, Shorman MA, Hassan H. J Chemother; 2012 Apr; 24(2):87-92. PubMed ID: 22546763 [Abstract] [Full Text] [Related]
2. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. Liu JW, Wang LS, Cheng YJ, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Chuang YC, Lin HC, Shi ZY, Kung HC, Huang CH, Tsao SM, Lu CT, Liao CH, Hsueh PR. Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353 [Abstract] [Full Text] [Related]
3. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. Tiengrim S, Tribuddharat C, Thamlikitkul V. J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S102-5. PubMed ID: 17718251 [Abstract] [Full Text] [Related]
4. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. Navon-Venezia S, Leavitt A, Carmeli Y. J Antimicrob Chemother; 2007 Apr; 59(4):772-4. PubMed ID: 17353223 [Abstract] [Full Text] [Related]
5. Unexpected tigecycline resistance among Acinetobacter baumannii Isolates: high minor error rate by Etest. Kulah C, Celebi G, Aktas E, Mengeloglu Z, Comert F, Ankarali H. J Chemother; 2009 Aug; 21(4):390-5. PubMed ID: 19622456 [Abstract] [Full Text] [Related]
6. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates]. Nayman Alpat S, Aybey AD, Akşit F, Ozgüneş I, Kiremitçi A, Usluer G. Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976 [Abstract] [Full Text] [Related]
7. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. Al-Sweih NA, Al-Hubail MA, Rotimi VO. J Chemother; 2011 Feb; 23(1):13-6. PubMed ID: 21482488 [Abstract] [Full Text] [Related]
8. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009. Morfin-Otero R, Dowzicky MJ. Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546 [Abstract] [Full Text] [Related]
9. Mechanisms of Resistance, Clonal Expansion, and Increasing Prevalence of Acinetobacter baumannii Strains Displaying Elevated Tigecycline MIC Values in Latin America. Costello SE, Gales AC, Morfin-Otero R, Jones RN, Castanheira M. Microb Drug Resist; 2016 Jun; 22(4):253-8. PubMed ID: 26716768 [Abstract] [Full Text] [Related]
10. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. Ricciardi R, Ricciardi AM, Danzi G. Infez Med; 2009 Dec; 17(4):236-9. PubMed ID: 20046104 [Abstract] [Full Text] [Related]
11. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates. Piewngam P, Kiratisin P. Int J Antimicrob Agents; 2014 Nov; 44(5):396-401. PubMed ID: 25442358 [Abstract] [Full Text] [Related]
12. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. Ni W, Cui J, Liang B, Cai Y, Bai N, Cai X, Wang R. J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963 [Abstract] [Full Text] [Related]
13. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Liao CH, Kung HC, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Cheng YJ, Lin HC, Shi ZY, Wang LS, Chuang YC, Tsao SM, Lu CT, Liu JW, Huang CH, Hsueh PR. Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S192-6. PubMed ID: 19013354 [Abstract] [Full Text] [Related]
14. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. Jamal W, Salama M, Dehrab N, Al Hashem G, Shahin M, Rotimi VO. J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588 [Abstract] [Full Text] [Related]
15. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Cai X, Yang Z, Dai J, Chen K, Zhang L, Ni W, Wei C, Cui J. Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729 [Abstract] [Full Text] [Related]
16. Rapid development of Acinetobacter baumannii resistance to tigecycline. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Pharmacotherapy; 2007 Aug; 27(8):1198-201. PubMed ID: 17655518 [Abstract] [Full Text] [Related]
17. Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii? Grandesso S, Sapino B, Amici G, Mazzucato S, Solinas M, Gion M. New Microbiol; 2014 Oct; 37(4):503-8. PubMed ID: 25387287 [Abstract] [Full Text] [Related]
19. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M. J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334 [Abstract] [Full Text] [Related]
20. In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period. Spiliopoulou A, Jelastopulu E, Vamvakopoulou S, Bartzavali C, Kolonitsiou F, Anastassiou ED, Christofidou M. J Chemother; 2015 Oct; 27(5):266-70. PubMed ID: 24827985 [Abstract] [Full Text] [Related] Page: [Next] [New Search]